Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.51 |
| ▸ | FABP6 | P51161 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4768302 | 0.99 | KDM4E (0.62) | KDM4EALDH1A1TDP1HTTMEN1 | |
| SCHEMBL4771108 | 0.91 | POLB (0.66) | KDM4EALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4766504 | 0.90 | KDM4E (0.62) | KDM4EALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4766164 | 0.88 | WNK1 (0.61) | KDM4EALDH1A1MEN1KMT2APOLB | |
| SCHEMBL4769312 | 0.88 | POLB (0.64) | KDM4EALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4769091 | 0.87 | POLB (0.72) | KDM4EALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4770714 | 0.86 | POLB (0.57) | KDM4EALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4769279 | 0.85 | POLB (0.57) | KDM4EALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4772944 | 0.83 | POLB (0.54) | KDM4EALDH1A1HTTMEN1KMT2A | |
| SCHEMBL4763764 | 0.83 | TGFBR1 (0.49) | KDM4EALDH1A1TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552188-B2 | Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds | KOWA CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | H1-0, DDAH1, AOC1 | KDM4E 3292/4885ALDH1A1 1083/4885TDP1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.